Please login to the form below

Not currently logged in
Email:
Password:

Sweden approves HPV vaccinations

Sanofi Pasteur MSD's Gardasil is to be recommended for use a cervical cancer vaccination program for schoolgirls throughout Sweden.

Sanofi Pasteur MSD's Gardasil is to be recommended for use a cervical cancer vaccination program for schoolgirls throughout Sweden.

Swedish government officials have advised that girls as young as 10 and 12 should start receiving free vaccinations through their schools' health authorities.

Gardasil, a quadrivalent vaccination, is used to inoculate against the human papillomavirus (HPV), which can lead to cervical cancer and other genital diseases..

Didier Hoch, president of Sanofi Pasteur MSD, said: "We hope that vaccination programmes will be implemented, so girls/women could soon have full access to these programmes that will help save lives and protect girls' and women's health from cervical cancer."

The Swedish Pharmaceuticals Benefits Board approved Gardasil for vaccination of girls between the ages of 13 and 17 in May 2007.

Gardasil has already been recommended in thirteen other European countries such as Germany, France, and the UK, as well as the US and Canada.

Swedish administrative scheduling should see Gardasil vaccinations officially approved for use in April 2008 and implemented by autumn 2008.

Cervical cancer is the second most common cause of cancer-related-death amongst women aged between 15 and 44-years-old in Europe.

27th February 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...

Infographics